Cohance Lifesciences Limited vs Gland Pharma Limited
Last updated: 5 November 2026
MoneyDock presents a detailed comparison between Cohance Lifesciences Limited (COHANCE.NS) and Gland Pharma Limited (GLAND.NS), two significant players in the Indian pharmaceutical sector. Both companies operate in the highly dynamic and essential healthcare industry, attracting investor attention due to their potential for growth and their roles in drug manufacturing and development. While Cohance Lifesciences focuses on a broader range of pharmaceutical activities, including intermediates, active pharmaceutical ingredients (APIs), and contract research and manufacturing services (CRAMS), Gland Pharma is a leading injectable-focused pharmaceutical company, primarily engaged in manufacturing and marketing of generic injectables. This comparison aims to provide investors with a clear, data-driven analysis of their current market positions, financial performance over the last year, and overall stability, helping them make informed investment decisions.
| Metric | Cohance Lifesciences (COHANCE.NS) | Gland Pharma (GLAND.NS) |
|---|---|---|
| Current Price | ₹449.00 | ₹3145.20 |
| 52W High | ₹537.35 | ₹3159.00 |
| 52W Low | ₹279.90 | ₹1596.80 |
| 1-Year Return | -16.44% | 90.21% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis
Valuation: Without available Trailing P/E ratios and Market Caps for both companies, a direct comparative valuation based on these specific metrics is not possible. However, looking at the current prices relative to their 52-week ranges, Gland Pharma is trading very close to its 52-week high (₹3145.20 vs ₹3159.00), suggesting a strong upward momentum or potentially a fully valued stock. Cohance Lifesciences, on the other hand, is trading at ₹449.00, significantly below its 52-week high of ₹537.35, which might indicate a more attractive entry point if future growth prospects are strong, or it could reflect ongoing challenges.
Returns: Gland Pharma clearly outperforms Cohance Lifesciences in terms of 1-Year Return, boasting an impressive 90.21% gain compared to Cohance's -16.44% loss. This significant difference highlights Gland Pharma's strong performance over the past year, rewarding its shareholders substantially. Cohance's negative return suggests it has faced headwinds or has not met investor expectations during the same period.
Stability: The 52-week range gives some insight into volatility. Gland Pharma's range is from ₹1596.80 to ₹3159.00, while Cohance Lifesciences ranges from ₹279.90 to ₹537.35. Gland Pharma's current price being so close to its 52-week high could be seen as a sign of strength and stability in its upward trend, or a potential resistance level. Cohance's current price being further from its high, combined with a negative 1-year return, could indicate more volatility or a downtrend in performance. The narrower absolute price range for Cohance might suggest lower price volatility in rupee terms, but its percentage movement from high to low is still significant.
Based on the provided data, Gland Pharma appears to be the winner in terms of recent market performance and positive momentum. Cohance Lifesciences, with its negative one-year return, presents a different risk-reward profile, potentially offering value if a turnaround is anticipated, but currently lagging in performance.
MoneyDock Verdict
For Aggressive Investors: Gland Pharma, with its strong 90.21% 1-Year Return and current price near its 52-week high, might appeal to aggressive investors looking for companies with strong recent momentum. However, they should be aware that trading near a 52-week high could limit immediate upside and increase risk if a correction occurs. Cohance Lifesciences, despite its negative return, might be considered by aggressive investors looking for a contrarian play or turnaround story, assuming a detailed fundamental analysis uncovers hidden value or future growth catalysts.
For Conservative Investors: Given the available data, neither stock provides sufficient information on traditional valuation metrics (P/E, Market Cap) to make a truly conservative assessment of intrinsic value. However, Gland Pharma's significant positive return indicates strong market favor, which might offer some comfort. Conservative investors would likely require more comprehensive financial data beyond these price-based metrics before making a decision. Cohance's negative return might deter conservative investors due to its underperformance.
For Long-Term SIP Investors: For long-term SIP investors, Gland Pharma's consistent upward trend over the last year suggests it could be a strong candidate for wealth accumulation, benefiting from rupee-cost averaging. Its leadership in injectables is a robust industry segment. Cohance Lifesciences would require a deeper dive into its long-term strategy, management quality, and competitive advantages to assess its suitability for a SIP, especially given its recent negative performance. Investors in Cohance would be betting on a significant recovery and sustained growth over the long haul.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.